sirdalud
sandoz d.d. - tizanidinas - tabletės - 2 mg; 4 mg - tizanidine
sirdalud
lex ano, uab - tizanidinas - tabletės - 2 mg - tizanidine
sirdalud
limedika, uab - tizanidinas - tabletės - 4 mg - tizanidine
sirdalud
ideal trade links, uab - tizanidinas - tabletės - 2 mg - tizanidine
sirdalud
ideal trade links, uab - tizanidinas - tabletės - 4 mg - tizanidine
tri-regol
gedeon richter plc - levonorgestrelis/etinilestradiolis+levonorgestrelis/etinilestradiolis+levonorgestrelis/etinilestradiolis - dengtos tabletės - 50 µg/30 µg + 75 µg/40 µg + 125 µg/30 µg - levonorgestrel and ethinylestradiol
aubagio
sanofi winthrop industrie - teriflunomide - išsėtinė sklerozė - selektyvūs imunosupresantai - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).
ciprofloxacin actavis
teva b.v. - ciprofloksacinas - plėvele dengtos tabletės - 500 mg - ciprofloxacin
tabrecta
novartis europharm limited - capmatinib dihydrochloride monohydrate - karcinoma, nesmulkiųjų ląstelių skausmas - antinavikiniai vaistai - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.
teriflunomide mylan
mylan pharmaceuticals limited - teriflunomide - išsėtinė sklerozė, grįžtamoji-pervedimo - imunosupresantai - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).